Daré Bioscience, Inc. (DARE) Stock Forecast 2026: P10, P50 & P90 — Probabli.AI
Timestamped DARE stock forecast with 1-year P10, P50, and P90 price estimates, scenario probabilities, definitions, sources, and limitations.
Direct answer: Daré Bioscience Inc. is a small-cap biotech with a strong focus in women's health therapeutics. The company has shown recent success, including the FDA fast track designation for DARE-BV and positive Phase 3 trials, which significantly boost its outlook. Although fundamental challenges exist, such as a reliance on future funding and commercialization hurdles, the stock's upside potential remains high, reflecting its strong analyst consensus and potential pipeline catalysts. The saved 1-year distribution is P10 $2.5, P50 $6.5, and P90 $12.
Last analyzed · Model: gpt-4o
Daré Bioscience, Inc. Forecast data
| Estimate | 1-year price | Meaning |
|---|
| P10 | $2.5 | Pessimistic plausible scenario |
| P50 | $6.5 | Median scenario |
| P90 | $12 | Optimistic plausible scenario |
What the numbers mean
P10, P50, and P90 are model-generated scenario estimates: roughly a pessimistic plausible outcome, a median outcome, and an optimistic plausible outcome. They are not calibrated confidence intervals.
Supporting analysis
Daré Bioscience's recent FDA fast track designation and positive phase 3 trial results suggest a significant upward momentum in the short term. However, the company's small revenue base and reliance on future milestones pose higher risks.
Sources and limitations
Market and company inputs are primarily sourced through Yahoo Finance and public financial-data interfaces. This page reports a saved AI-generated scenario analysis as of the timestamp above; it is not live data, audited probability, financial advice, or a guaranteed return.
Frequently asked questions
When was this DARE analysis generated?
May 4, 2026.
Is this a guaranteed DARE prediction?
No. It is a model-generated scenario assessment with material uncertainty.
View the full DARE stock analysis · DARE sentiment · Methodology · Accuracy & validation
The information on this page is for educational and informational purposes only and does not constitute professional financial advice.